EX-99.1 2 ea023405901ex99-1_optimize.htm PRESS RELEASE, DATED MARCH 12, 2025 Exhibit 99.1 OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results Q4 revenue of $32.3 million, increasing 14% year-over-year Q4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68% Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023 ──────────────────────────────────────────────────────────────────────────── Waltham, MA. - March 12, 2025 - OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare techno logy solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2024. For the Year Ended December 31, Key Performance Indicators (KPIs)* 2024 2023 …
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
OptimizeRx Corporation
OPRXNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 12, 2025, OptimizeRx Corporation issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2024, providing Key Performance Indicators and initial 2025 guidance. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.…
Company context
OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.